Generic Name and Formulations:
Thiothixene 1mg, 2mg, 5mg, 10mg; caps.
Indications for Thiothixene:
Individualize. Mild: initially 2mg three times daily, may subsequently increase to 15mg/day. Severe: initially 5mg twice daily. Usual optimal dose: 20–30mg daily; if needed, may increase to max 60mg/day.
Circulatory collapse. Coma. CNS depression. Blood dyscrasias.
Elderly with dementia-related psychosis (not approved use): increased risk of death. History of convulsive disorders or alcohol withdrawal. Exposure to extreme heat. Cardiovascular disease. Pre-existing low WBC or history of drug induced leukopenia/neutropenia; monitor CBCs during 1st few months of treatment. If significant neutropenia occurs; monitor for fever and signs of infections; discontinue if ANC<1000/mm3. Hepatic impairment. Neonates: risk of extrapyramidal and/or withdrawal symptoms post delivery (due to exposure during 3rd-trimester pregnancy). Pregnancy.
Additive effects with hypotensive agents, CNS depressants and alcohol. Potentiates barbiturates. Antagonized by carbamazepine. Caution with concomitant atropine or related drugs.
Tardive dyskinesia, hypotension, drowsiness, insomnia, jaundice, blood dyscrasias, may mask emetic signs of overdosage or disease, lowered seizure threshold, rash, photosensitivity, hyperprolactinemia, anticholinergic effects, pigmentary retinopathy, lenticular pigmentation, extrapyramidal reactions, neuroleptic malignant syndrome (monitor).
Endocrinology Advisor Articles
- Imaging Studies in Hypothyroidism Evaluation Linked to Unnecessary Risks
- Once-Weekly Omarigliptin Improves Glycemic Control in Type 2 Diabetes
- Insulin Glargine Associated With Breast Cancer Risk in T2D
- Transoral Endoscopic Thyroidectomy Vestibular Approach: Safety and Outcomes
- High Grip Strength Associated With Lower Risk for Diabetes-Related AEs
- Update on Vitamin D and Calcium Supplements for Reducing Fracture Risk
- Lower Risk for SGLT2i-Associated Genitourinary Infection With DPP-4i
- Severe Hypoglycemia Associated With Increased Mortality Risk in T2D
- Efficacy of CGM in Preterm Infants of Mothers With Diabetes
- SSRIs and SNRIs Linked to Type 2 Diabetes in Children, Adolescents
- Increased Risk of Diabetes, Post-Diabetes Pneumonia for Patients With COPD
- Pancreatic Exocrine Dysfunction Occurs After Islet Autoimmunity in T1D
- T2D in African American Women Ups ER-negative Breast Cancer Risk
- High-Sensitivity CRP and LDL-C Predictive of Subsequent MACE in T2D
- Risks Associated With Denosumab Discontinuation